chairman
pharmaceutical science
oxyrane
Belgium
Former President and Chief Executive Officer of BioVex until he sold the company to Amgen in 2011. Prior to Biovex, Mr. Astley-Sparke was an investment banker with Chase/Robert Fleming. Mr. Astley-Sparke is a chartered accountant and holds a BA in Cellular Pathology and Molecular Pathology from Bristol University (UK).
pathology molecular pathology virulence of microbiology